Evidence map›Paper›PMID 41989083›Full record

ArticleJACC. Case reports2026

5-Year Follow-Up After Transcatheter Mitral Valve Replacement Using the Cardiovalve System.

Rimantas Benetis, Matteo Saccocci, Egle Rumbinaite, Vaida Mizariene, Ramunas Unikas, Antanas Jankauskas, Michel Zuber, Francesco Maisano

Registry-linked trialAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03958773 (Cardiovalve Transfemoral Mitral Valve System in Patients at High Surgical Risk With Severe Mitral Regurgitation), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03958773 naenrolling by invitationnot on this map

Cardiovalve Transfemoral Mitral Valve System in Patients at High Surgical Risk With Severe Mitral Regurgitation

TypeinterventionalSponsorCardiovalve Ltd.Ran2017 to 2026Enrolled10ConditionsMitral RegurgitationArmsCardiovalve transfemoral Mitral valve system
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rimantas BenetisDepartment of Cardiac, Thoracic and Vascular Surgery, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania. Electronic address: Rimantas.Benetis@lsmu.lt.
Matteo SaccocciHeart Valve Center - IRCCS Ospedale San Raffaele, Università Vita Salute, Milano, Italy.
Egle RumbinaiteDepartment of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Vaida MizarieneDepartment of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Ramunas UnikasDepartment of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Antanas JankauskasDepartment of Radiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Michel ZuberZurich University Hospital, Zurich, Switzerland.
Francesco MaisanoHeart Valve Center - IRCCS Ospedale San Raffaele, Università Vita Salute, Milano, Italy; Università Vita Salute San Raffaele, Milano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere mitral regurgitation (MR) in high-risk patients often precludes surgical repair, and suboptimal anatomy may limit edge-to-edge repair. Transcatheter mitral valve replacement (TMVR) has emerged as an alternative; however, long-term durability data remain limited. FIRST IN HUMAN/EARLY REPORTS SUMMARY: We report a 75-year-old man with ischemic MR (Carpentier IIIb), treated with transfemoral TMVR using the Cardiovalve device within the Cardiovalve FIM study (NCT03958773). The procedure was successful, with no MR postprocedural and only minor periprocedural complications. DISCUSSION: At 5-year follow-up, the patient remained clinically stable (NYHA functional class I) with preserved valve function, and absence of degeneration, thrombosis, or left ventricular outflow tract obstruction. This represents the longest reported follow-up of Cardiovalve to date and suggests sustained clinical and hemodynamic benefit. NOVELTY: This is the first report of a 5-year follow-up after transfemoral TMVR with Cardiovalve, demonstrating excellent durability and safety. TAKE-HOME MESSAGE: Cardiovalve TMVR offers a promising long-term option for high-risk MR patients with sustained clinical and echocardiographic success over 5 years.

Indexed as

mitral regurgitationmitral valvemitral valve replacementTMVRtranscatheter procedure

Identifiers

PMID41989083
PMCPMC13104050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.